Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- David Cohan, MD/FACS
Replimune, Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
34 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University Hospital Olomouc
Olomouc, Czechia
- Fn Kralovske Vinohrady
Prague, Czechia
- Fakultni Thomayerova Nemocnice
Prague, Czechia
- Centre Georges Francois Leclerc, Department of Oncology
Dijon, France
- Centre Leon Berard
Lyon, France
- Assistance Publique Hopitaux de Marseille
Marseille, France
- Chu Nimes, Instiut de Cancerologie Du Gard, Medical Oncology
Nîmes, France
- Institut Gustave Roussy Paris
Villejuif, France
- Charite University Hospital of Berlin, Comprehensive Cancer Center
Berlin, Germany
- Universitatsklinik Jena Klinik Und Poliklinik Fur Hals-, Nasen - Und Ohrenheilkunde
Jena, Germany
- University Hospital Leipzig Clinic and Polyclinic for Otorhinolaryngology
Leipzig, Germany
- Lmu Klinikum, Medizinische Klinik Und Poliklinikum Iii
Munich, Germany
- Universitatsklinikum Ulm
Ulm, Germany
- University General Hospital Attikon
Chaïdári, Greece
- Agios Lukas Hospital
Thessaloniki, Greece
- Szpital Specjalistyczny Im Ludwika Rydygiera W Krakowie Sp Z Oo, Department of Clinical Oncology
Krakow, Poland
- Vall D'Hebron University Hospital, Vall D' Hebron Institute of Oncology (vhio)
Barcelona, Spain
- Hospital Universitario Hm Sanchinarro
Madrid, Spain
- la Paz Univeristy Hospital, Universidad Autonoma de Madrid
Madrid, Spain
- Clinica Universitaria de Navarra
Pamplona, Spain
- Fundacion Instituto Valenciano de Oncologia
Valencia, Spain
- the Royal Marsden Nhs Foundation Trust
London, United Kingdom
- University of California San Diego, Ucsd
La Jolla, California, United States
- Ucla Medicine Division of Hematology-Oncology
Los Angeles, California, United States
- Usc Norris Comprehensive Cancer Center
Los Angeles, California, United States
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
- University of Cincinnati Medical Center
Cincinnati, Ohio, United States
- Cleveland Clinic
Cleveland, Ohio, United States
- Thomas Jefferson University City Center and Abington
Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center, Upmc
Pittsburgh, Pennsylvania, United States
- Jefferson Health Abington Asplunhd Cancer Pavillion
Willow Grove, Pennsylvania, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- University of Washington / Fred Hutchinson Cancer Center
Seattle, Washington, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jan 2024
- Primary completion
- 1 Mar 2026
- Completion
- 1 Jun 2026
- Last update posted
- 11 Mar 2025
- Registered enrollment
- 0
- Registry id
- NCT05743270
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.